20 May 2013
Keywords: Eisai, Halaven, UK, NICE, Cost effectiveness
Article | 17 November 2011
In a second negative from the UK’s National Institute for Health and Clinical Excellence, in final draft guidance ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
17 November 2011
17 May 2013
© 2013 thepharmaletter.com